RT Journal Article
SR Electronic
T1 Trajectory of COVID-19 epidemic in Europe
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.26.20202267
DO 10.1101/2020.09.26.20202267
A1 Colombo, Marco
A1 Mellor, Joseph
A1 Colhoun, Helen M
A1 M Gomes, M Gabriela
A1 McKeigue, Paul M
YR 2020
UL http://medrxiv.org/content/early/2020/09/28/2020.09.26.20202267.abstract
AB The classic Susceptible-Infected-Recovered model formulated by Kermack and McKendrick [1] assumes that all individuals in the population are equally susceptible to infection. From fitting such a model to the trajectory of mortality from COVID-19 in 11 European countries up to 4 May 2020 Flaxman et al. concluded that “major non-pharmaceutical interventions – and lockdowns in particular – have had a large effect on reducing transmission” [2]. We show that relaxing the assumption of homogeneity to allow for individual variation in susceptibility or connectivity gives a model that has better fit to the data and more accurate 14-day forward prediction of mortality. Allowing for heterogeneity reduces the estimate of “counterfactual” deaths that would have occurred if there had been no interventions from 3.2 million to 262,000, implying that most of the slowing and reversal of COVID-19 mortality is explained by the build-up of herd immunity. The estimate of the herd immunity threshold depends on the value specified for the infection fatality ratio (IFR): a value of 0.3% for the IFR gives 15% for the average herd immunity threshold.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Self-audit for research not involving human subjects as specified by Usher Research Ethics Group, University of EdinburghAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and modelling code are freely available at the URL given below. https://github.com/mcol/covid19model